Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
BeOne Medicines
Lyell Immunopharma, Inc.
Curis, Inc.
BeOne Medicines
Innate Pharma
Bristol-Myers Squibb
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche
Artiva Biotherapeutics, Inc.
AstraZeneca
Vironexis Biotherapeutics Inc.
Galapagos NV
Genmab
Cho Pharma Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
Celgene
Werewolf Therapeutics, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Eli Lilly and Company
CellCentric Ltd.
Incyte Corporation
Acerta Pharma BV
CRISPR Therapeutics
Ipsen
CRISPR Therapeutics
Bristol-Myers Squibb
Incyte Corporation
Acerta Pharma BV
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Genmab
Genentech, Inc.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Juventas Cell Therapy Ltd.
Estrella Immunopharma, Inc.
Indapta Therapeutics, INC.
Gilead Sciences
Novartis
Xynomic Pharmaceuticals, Inc.
Gamida Cell ltd
Aprea Therapeutics
Beijing InnoCare Pharma Tech Co., Ltd.
ImmunityBio, Inc.
Dizal Pharmaceuticals
Kronos Bio